GlaxoSmithkline Consumer reports 8% fall in Q3 net profit

Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) | Consumer Food | FMCG | BSE: 500676 | NSE: GSKCONS

14 Feb 2017 Evaluate

GlaxoSmithkline Consumer Healthcare has reported results for third quarter ended December 31, 2016.

The company has reported 8.25% fall in its net profit at Rs 136.41 crore for the quarter under review as compared to Rs 148.68 crore for the same quarter in the previous year. Total income of the company decreased by 11.94% at Rs 1016.09 crore for the quarter under review as compared Rs 1153.86 crore for the corresponding quarter previous year.

GlaxoSmithkline Consumer Healthcare’s core business is manufacturing of health drinks under the brand Horlicks. It exports products to countries like Bangladesh, Myanmar, Sri Lanka, Middle East, Fiji, Mauritius, Nepal, Bhutan and many more.

Peers

Company Name	CMP
Nestle India	1343.65
Varun Beverages	431.50
Britannia Industries	4843.60
LT Foods	408.30
Hatsun Agro Product	1114.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.